Hepatitis C: the liver disease that is now curable in most people

What makes hepatitis C different from hepatitis B?

Hepatitis C virus (HCV) infects liver cells like hepatitis B, but the two viruses behave differently in three important ways. First, where most adults clear a hepatitis B infection on their own, hepatitis C becomes chronic in 70 to 85 percent of people who are infected. Second, unlike hepatitis B, there is no vaccine against hepatitis C. Third, and this is the central message of this article, hepatitis C can be cured in over 95 percent of cases with a modern antiviral course that takes less than three months.

A 2026 review by El-Kassas and Esmat in the Arab Journal of Gastroenterology noted that hepatitis C transformed Egypt's public health landscape over three decades and that the national elimination response of 2018 to 2020 moved it from a potential catastrophe to an international success story. Understanding this history matters because it illustrates what is possible when early diagnosis is combined with affordable, accessible treatment.

The disease is clinically silent in most of its course. Someone infected with HCV can live for twenty years without any clear symptoms while damage accumulates in the liver. When symptoms such as severe fatigue, jaundice and abdominal swelling finally appear, significant fibrosis may already be present. This silence is precisely why testing matters even when you feel entirely well.

How does hepatitis C spread?

Hepatitis C spreads exclusively through blood-to-blood contact. In the Arab world, the large-scale spread of the virus in Egypt was linked historically to injection campaigns against schistosomiasis using shared needles in the mid-twentieth century. Today, the main transmission routes are: sharing needles, syringes or drug preparation equipment; medical or surgical procedures using inadequately sterilised instruments in resource-limited settings; tattooing and body piercing with non-sterile equipment; and, less commonly, sexual contact when there is blood involvement.

A 2020 systematic review published in the journal Addiction examining hepatitis C among people who inject drugs across the Middle East and North Africa found significant variation in infection rates between countries but consistently high prevalence in this group, highlighting the need for targeted harm reduction as part of any regional elimination strategy. A 2018 overview in the World Journal of Gastroenterology catalogued prevalence data across the region and found Egypt historically far ahead of neighbouring countries, with Jordan, Iraq and Libya also carrying notable rates.

Hepatitis C does not spread through handshakes, hugs, coughing, sneezing, sharing food or drink, or using the same toilet. Sexual transmission is possible but much less efficient than for hepatitis B or HIV, and most long-term partners of chronically infected people do not acquire the virus. Mother-to-child transmission at birth occurs but at much lower rates than for hepatitis B, typically between 5 and 7 percent in the absence of complications.

Who should get tested for hepatitis C?

Because the infection is silent for so long, targeted testing based on risk history is more effective than waiting for symptoms. Anyone who had a surgical procedure, blood transfusion, or injection with shared equipment before blood supply screening became mandatory in their country, which in many Arab countries was the 1990s, should be tested once regardless of how well they feel. This single test could find an infection that has been silently scarring the liver for decades.

The diagnostic pathway starts with an anti-HCV antibody test. A positive result means the immune system has been exposed to the virus at some point, but it does not by itself confirm active infection, because antibodies persist long after recovery. The confirmatory step is an HCV RNA test (PCR), which detects the actual virus in the blood. Only a positive PCR confirms that the infection is currently active and that treatment is needed. A 2023 study in Jordan examining viral genotypes found that the modern pan-genotypic drugs work effectively across most genotypes circulating in the region, meaning genotype testing does not always change the treatment decision.

In countries where national screening programmes exist, such as Egypt's expanded programme, the process has been streamlined into community health centres and even mobile units. In countries without a national programme, a simple blood test from any accredited laboratory is the starting point. Testing is painless, often inexpensive, and the consequences of finding the infection early are dramatically better than finding it after cirrhosis has developed.

How do the new hepatitis C medicines work?

Before 2014, treating hepatitis C meant months of interferon injections with severe side effects, mediocre success rates and significant expense. Direct-acting antivirals (DAAs) changed everything. These drugs block the enzymes the HCV virus needs to replicate, shutting down viral production rapidly. Treatment courses now last 8 to 12 weeks in most cases. The drugs are taken as one or two tablets daily with few meaningful side effects.

The most widely used combinations in the Arab world include sofosbuvir with daclatasvir, sofosbuvir with ledipasvir, and glecaprevir with pibrentasvir. The last of these is fully pan-genotypic, meaning it works against all six major hepatitis C genotypes without needing a genotype test first. The choice between combinations depends on the patient's kidney function, any cirrhosis present, and what medications they already take.

The treatment goal is what clinicians call SVR, or sustained virological response, which means HCV RNA is undetectable twelve weeks after completing treatment. Achieving SVR is equivalent to cure. In the absence of re-exposure, the virus does not return. Liver function begins to improve after SVR, and mild to moderate fibrosis can partially reverse over the following years.

Egypt's hepatitis C campaign: what a national success looks like

Egypt entered the modern era of direct-acting antivirals carrying the world's highest per-capita hepatitis C burden, a consequence of mass injection campaigns against schistosomiasis in the 1950s through 1980s during which needles were reused between patients. Between 2018 and 2020, the Egyptian government launched the 100 Million Health initiative, which systematically screened the adult population and offered free treatment to all who tested positive.

A 2024 study in the journal Pathogens confirmed that the campaign screened tens of millions of people and treated a historic number of infected individuals, achieving substantial reductions in national prevalence and providing a model that the WHO has since cited as a global benchmark. The critical enablers were generic drug pricing negotiated to a fraction of Western costs, deployment of screening teams to community health units and schools, and integration of treatment with primary care rather than specialist centres.

For any individual reading this, the Egyptian campaign carries one clear message: the treatment is real, effective, affordable and accessible through public health systems. Barriers to treatment are diminishing, and the window to cure an infection caught decades ago remains fully open.

What happens to the liver after cure?

Achieving SVR stops the virus from damaging the liver, but it does not instantly reverse all damage already done. The trajectory after cure depends heavily on how much fibrosis was present before treatment. Patients with mild or moderate fibrosis (stages F0 to F2 on the Metavir scale) often show measurable improvement in liver stiffness over the two to three years following cure. This is a genuine biological reversal of early-stage scarring.

Patients who reach cure at stage F3 or with full cirrhosis (F4) experience the most critical benefit in a different form: arresting further progression and substantially reducing the risk of liver cancer. The risk of hepatocellular carcinoma does not disappear entirely after SVR in people who had cirrhosis, which is why ongoing surveillance every six months with ultrasound and alpha-fetoprotein measurement remains necessary even after the virus is gone.

One important caveat: curing hepatitis C does not produce lasting immunity. Unlike measles or chickenpox, recovery from HCV does not prevent re-infection. If a cured person is subsequently exposed to contaminated blood through a shared needle or unsafe procedure, they can be infected again and will need another treatment course. Prevention of re-exposure is therefore as important after cure as it is before.

Warning signs that should be assessed urgently

Most people with chronic hepatitis C have no symptoms that direct them to seek care. The most common complaint is fatigue, which is non-specific and easy to attribute to other causes. When more specific symptoms appear, they usually indicate that liver function is compromised and prompt evaluation is needed rather than watchful waiting.

Jaundice, the yellowing of skin or eyes, signals impaired bilirubin processing and warrants same-day assessment. Upper right abdominal pain can indicate liver inflammation or enlargement. Unexplained weight loss over weeks, combined with fatigue and loss of appetite, warrants investigation. Abdominal swelling from fluid accumulation and easy bruising or bleeding indicate advanced liver disease requiring urgent specialist input.

After cure: staying on top of follow-up with Sihtak

After completing a hepatitis C treatment course, you will have an HCV RNA test twelve weeks later to confirm SVR. Keep a clear record of when treatment started, what drugs you took, and when SVR was confirmed. This information is essential for any future medical contact, including if you travel or change doctors.

If you had cirrhosis before treatment, six-monthly surveillance continues indefinitely regardless of SVR. Many people find it difficult to remember their last ultrasound date or whether their AFP has been checked recently. Using the Sihtak app to log each result and set reminders for the next appointment creates a simple, reliable health record that travels with you. This kind of continuity of monitoring is what converts a successful cure into decades of protected liver health.

Sources

• Gomaa A, Gomaa M, Allam N et al: Hepatitis C Elimination in Egypt: Story of Success, Pathogens (Basel, Switzerland), 2024
• Chaabna K, Cheema S, Abraham A et al: Systematic overview of hepatitis C infection in the Middle East and North Africa, World journal of gastroenterology, 2018
• El-Kassas M, Esmat G: Three decades of change: schistosomiasis, hepatitis C, and the rise of metabolic dysfunction-associated steatotic liver disease in Egypt, Arab journal of gastroenterology, 2026
• Fuentes A, Abu-Dayyeh I, de Salazar A et al: Molecular characterization of patients with chronic hepatitis C virus infection in Jordan, International journal of infectious diseases, 2023
• Mahmud S, Mumtaz GR, Chemaitelly H et al: The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa, Addiction, 2020
• World Health Organization: Hepatitis C fact sheet, WHO, 2024